
Enovis Corporation
ENOV
Updated: 22/09/2026, 08:43:10
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
No summaries found.
- Share price
- $18.04
- Market cap
- $1.04B
- Exchange
- NYSE
- Currency
- USD
- CEO
- Damien McDonald
- Employees
- 7,802
- IPO date
- 08/05/2008
- Beta
- 1.429
- Last dividend
- $0.00
- Day range
- $17.47 – $18.04
- 52-week range
- $17.30 – $34.28
- 1-day performance
- 0.00%
- 1-year performance
- 4.28%
- Current drawdown (1Y)
- -47.37%
- CIK
- 0001420800
- CUSIP
- 194014502
- ISIN
- US1940145022
- Created
- 07/12/2025, 03:47:34
- Last update
- 22/09/2026, 08:43:10
Track Enovis Corporation with an AI analyst
See which prediction-market events move ENOV, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Does Enovis (ENOV) Have the Potential to Rally 65.45% as Wall Street Analysts Expect?
Zacks Investment Research • STOCK • 13/05/2026, 12:55:28
Enovis Q1 Earnings Call Highlights
MarketBeat • STOCK • 10/05/2026, 06:07:33
Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 07/05/2026, 17:11:27
Enovis Announces First Quarter 2026 Results
GlobeNewsWire • STOCK • 07/05/2026, 08:01:00
Analyst Backs Enovis On Cash Flow Turnaround
Benzinga • STOCK • 17/04/2026, 15:45:45
Enovis to Host First Quarter 2026 Results Conference Call on May 7th
GlobeNewsWire • STOCK • 10/04/2026, 10:00:00
Wall Street Analysts See a 100.71% Upside in Enovis (ENOV): Can the Stock Really Move This High?
Zacks Investment Research • STOCK • 24/03/2026, 11:56:30
Enovis Corporation (ENOV) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 27/02/2026, 03:27:50
Enovis (ENOV) Q4 Earnings Beat Estimates
Zacks Investment Research • STOCK • 26/02/2026, 10:15:52
Update: Enovis Announces Fourth Quarter and Full Year 2025 Results
GlobeNewsWire • STOCK • 26/02/2026, 07:33:00
Enovis Announces Fourth Quarter and Full Year 2025 Results
GlobeNewsWire • STOCK • 26/02/2026, 07:10:00